Quantum Private Wealth LLC Boosts Stock Holdings in Taysha Gene Therapies, Inc. $TSHA

Quantum Private Wealth LLC boosted its position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) by 3.1% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 815,976 shares of the company’s stock after buying an additional 24,500 shares during the quarter. Quantum Private Wealth LLC’s holdings in Taysha Gene Therapies were worth $1,885,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently made changes to their positions in the company. Granahan Investment Management LLC lifted its position in shares of Taysha Gene Therapies by 0.3% during the 1st quarter. Granahan Investment Management LLC now owns 1,640,793 shares of the company’s stock valued at $2,281,000 after buying an additional 4,412 shares during the last quarter. Rhumbline Advisers raised its stake in Taysha Gene Therapies by 7.0% in the 1st quarter. Rhumbline Advisers now owns 205,462 shares of the company’s stock valued at $286,000 after acquiring an additional 13,383 shares during the period. May Hill Capital LLC bought a new stake in Taysha Gene Therapies in the 2nd quarter valued at about $37,000. Profund Advisors LLC purchased a new stake in Taysha Gene Therapies during the second quarter valued at about $61,000. Finally, Ethic Inc. bought a new position in Taysha Gene Therapies during the second quarter worth about $67,000. 77.70% of the stock is currently owned by institutional investors.

Taysha Gene Therapies Stock Up 5.0%

TSHA opened at $4.19 on Friday. The firm has a market capitalization of $1.15 billion, a P/E ratio of -12.70 and a beta of 1.00. Taysha Gene Therapies, Inc. has a one year low of $1.05 and a one year high of $5.51. The company has a fifty day moving average price of $4.19 and a 200-day moving average price of $3.22. The company has a debt-to-equity ratio of 0.23, a current ratio of 10.48 and a quick ratio of 10.48.

Taysha Gene Therapies (NASDAQ:TSHA) last posted its quarterly earnings data on Tuesday, November 4th. The company reported ($0.09) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.09). Taysha Gene Therapies had a negative return on equity of 67.26% and a negative net margin of 1,144.97%. Equities research analysts expect that Taysha Gene Therapies, Inc. will post -0.35 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the stock. Cantor Fitzgerald reiterated an “overweight” rating and issued a $13.00 target price on shares of Taysha Gene Therapies in a research note on Friday, November 14th. Citigroup reaffirmed an “outperform” rating on shares of Taysha Gene Therapies in a report on Wednesday, November 5th. Raymond James Financial began coverage on shares of Taysha Gene Therapies in a research note on Tuesday, October 21st. They issued a “strong-buy” rating and a $13.00 price objective for the company. Wells Fargo & Company boosted their target price on shares of Taysha Gene Therapies from $7.50 to $8.00 and gave the company an “overweight” rating in a report on Wednesday, August 13th. Finally, Needham & Company LLC restated a “buy” rating and set a $10.00 target price on shares of Taysha Gene Therapies in a research report on Friday, October 17th. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, Taysha Gene Therapies currently has a consensus rating of “Moderate Buy” and an average target price of $10.30.

Insider Activity

In other news, insider Sukumar Nagendran sold 200,000 shares of Taysha Gene Therapies stock in a transaction dated Wednesday, September 10th. The stock was sold at an average price of $3.23, for a total transaction of $646,000.00. Following the completion of the sale, the insider owned 1,006,439 shares in the company, valued at approximately $3,250,797.97. This trade represents a 16.58% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 3.78% of the company’s stock.

Taysha Gene Therapies Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.